

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-29 (canceled).

¹ ~~30~~. (Previously Presented) An isolated antibody or antibody fragment which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN).

² ~~31~~. (Previously Presented) An antibody or antibody fragment according to claim ¹ ~~30~~, which comprises a mammalian antibody-antigen binding domain.

³ ~~32~~. (Previously Presented) An antibody or antibody fragment according to claim ² ~~31~~, wherein said antibody-antigen binding domain is of human origin.

⁴ ~~33~~. (Previously Presented) An antibody or antibody fragment according to claim ¹ ~~30~~, which binds to FN containing ED-B after treatment of the FN with the protease thermolysin.

⁵ ~~34~~. (Previously Presented) An antibody or antibody fragment according to claim ¹ ~~30~~, which binds directly to the ED-B domain portion of recombinant FN containing type III homology repeats which include the ED-B domain.

⁶ ~~35~~. (Previously Presented) An antibody or antibody fragment according to claim ¹ ~~30~~, whose binding to B-FN is inhibited by the ED-B domain.

⁷ ~~36~~. (Previously Presented) An antibody or antibody fragment according to claim ¹ ~~30~~, which binds to B-FN from human, mouse, rat, chicken, and any other species in which the ED-B domain is conserved.

8 37. (Previously Presented) An antibody or antibody fragment according to claim 30, which binds to B-FN without treatment of the FN with N-glycanase.

38. (Previously Presented) An antibody or antibody fragment according to claim 30, having a variable heavy (VH) chain region of the sequence (aa 1 Glu – aa 98 Arg inclusive in Figure 1) (SEQ ID NO: 9) and the CDR3 sequence Ser Leu Pro Lys (SEQ ID NO: 12).

9 39. (Previously Presented) An antibody or antibody fragment according to claim 30, having a variable heavy (VH) chain region of the sequence (aa 1 Glu – aa 98 Arg inclusive in Figure 1A) (SEQ ID NO: 9) and the CDR3 sequence Gly Val Gly Ala Phe Arg Pro Tyr Arg Lys His Glu (SEQ ID NO: 1).

10 40. (Previously Presented) An antibody or antibody fragment according to claim 30, having a variable light (VL) chain region of the sequence (aa 1 Ser – aa 90 Ser inclusive in Figure 1B) (SEQ ID NO: 10) and the remainder of the CDR3 sequence as Pro Val Val Leu Asn Gly Val Val (SEQ ID NO: 13).

11 41. (Previously Presented) An antibody or antibody fragment according to claim 30, having a variable light (VL) chain region of the sequence (aa 1 Ser – aa 90 Ser inclusive in Figure 1B) (SEQ ID NO: 11) and the remainder of the CDR3 sequence as Pro Phe Glu His Asn Leu Val Val (SEQ ID NO: 14).

12 42. (Previously Presented) An antibody or antibody fragment according to claim 30, having a variable heavy (VH) chain region of the sequence (aa 1 Glu – aa 98 Arg inclusive in Figure 1A) (SEQ ID NO: 9) and the CDR3 sequence.

~~13~~ ~~43.~~ (Previously Presented) An antibody or antibody fragment according to claim ~~30~~, which, when measured as a purified monomer, has a dissociation constant (K_d) of about $6 \times 10^{-8}M$ or less for ED-B FN.

~~14~~ ~~44.~~ (Previously Presented) An antibody or antibody fragment according to claim ~~30~~, which comprises an scF_v molecule.

~~15~~ ~~45.~~ (Previously Presented) An antibody or antibody fragment according to claim ~~30~~, which comprises a dimeric scF_v molecule.

~~16~~ ~~46.~~ (Currently Amended) An antibody or antibody fragment according to claim ~~30~~, which ~~comprises~~ is CGS-1 or CGS-2, or a fragment thereof.

~~17~~ ~~47.~~ (Previously Presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim ~~30~~, in an effective amount for binding thereof to a fibronectin ED-B-containing cell, and a pharmaceutically-acceptable excipient.

Claims 48-52 (canceled).

~~18~~ ~~53.~~ (Previously Presented) A diagnostic kit comprising an antibody or antibody fragment according to claim ~~30~~ and one or more reagents that allow the determination of the binding of said antibody or antibody fragment to a cell.

~~19~~ ~~54.~~ (Previously Presented) An antibody or antibody fragment of claim ~~30~~, which is isolated from a synthetic molecular library.

~~20~~ ~~55.~~ (Previously Presented) An antibody or antibody fragment of claim ~~30~~, which is not naturally occurring.

56. (Canceled)
- 21₅₇. (Previously Presented) An antibody of claim ~~30~~¹
- 22₅₈. (Previously Presented) An antibody fragment of claim ~~30~~¹
- 23₅₉. (Previously Presented) An antibody or antibody fragment of Claim ~~30~~¹ which binds in vivo directly to said ED-B oncofetal domain.
- 24₆₀. (Previously Presented) An antibody or antibody fragment of Claim ~~30~~¹ which binds in a patient directly to said ED-B oncofetal domain.
- 25₆₁. (Previously Presented) A pharmaceutical composition for cancer therapy or diagnostics comprising an antibody or antibody fragment according to claim ~~30~~¹, in an effective amount for binding thereof to a fibronectin ED-B-containing cell, and a pharmaceutically-acceptable excipient.
- 26₆₂. (New) An antibody fragment of claim ~~30~~¹ which is a Fab, Fv, dAb, Fd, Fab', F(ab')₂, Fabc, Facb or diabody fragment.
- 27₆₃. (New) An antibody of claim ~~30~~¹ which is of the IgG isotype.